These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 24053309)

  • 1. Inflammation and prostate cancer: the role of interleukin 6 (IL-6).
    Nguyen DP; Li J; Tewari AK
    BJU Int; 2014 Jun; 113(6):986-92. PubMed ID: 24053309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway.
    Steiner H; Godoy-Tundidor S; Rogatsch H; Berger AP; Fuchs D; Comuzzi B; Bartsch G; Hobisch A; Culig Z
    Am J Pathol; 2003 Feb; 162(2):655-63. PubMed ID: 12547723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells.
    Sanford DC; DeWille JW
    Prostate; 2005 May; 63(2):143-54. PubMed ID: 15486993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
    Godoy-Tundidor S; Cavarretta IT; Fuchs D; Fiechtl M; Steiner H; Friedbichler K; Bartsch G; Hobisch A; Culig Z
    Prostate; 2005 Jul; 64(2):209-16. PubMed ID: 15712220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
    Wallner L; Dai J; Escara-Wilke J; Zhang J; Yao Z; Lu Y; Trikha M; Nemeth JA; Zaki MH; Keller ET
    Cancer Res; 2006 Mar; 66(6):3087-95. PubMed ID: 16540658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer.
    Nguyen DP; Li J; Yadav SS; Tewari AK
    BJU Int; 2014 Aug; 114(2):168-76. PubMed ID: 24215139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6 regulation of prostate cancer cell growth.
    Culig Z; Steiner H; Bartsch G; Hobisch A
    J Cell Biochem; 2005 Jun; 95(3):497-505. PubMed ID: 15838876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Principles of interleukin (IL)-6-type cytokine signalling and its regulation.
    Heinrich PC; Behrmann I; Haan S; Hermanns HM; Müller-Newen G; Schaper F
    Biochem J; 2003 Aug; 374(Pt 1):1-20. PubMed ID: 12773095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-6 and PPARgamma signalling in human PC-3 prostate cancer cells.
    Pitulis N; Papageorgiou E; Tenta R; Lembessis P; Koutsilieris M
    Anticancer Res; 2009 Jun; 29(6):2331-7. PubMed ID: 19528499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.
    Hobisch A; Eder IE; Putz T; Horninger W; Bartsch G; Klocker H; Culig Z
    Cancer Res; 1998 Oct; 58(20):4640-5. PubMed ID: 9788616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.
    Malinowska K; Neuwirt H; Cavarretta IT; Bektic J; Steiner H; Dietrich H; Moser PL; Fuchs D; Hobisch A; Culig Z
    Endocr Relat Cancer; 2009 Mar; 16(1):155-69. PubMed ID: 19011039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth.
    Zoubeidi A; Rocha J; Zouanat FZ; Hamel L; Scarlata E; Aprikian AG; Chevalier S
    Mol Cancer Res; 2009 Jan; 7(1):142-55. PubMed ID: 19147545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.
    Lee LF; Louie MC; Desai SJ; Yang J; Chen HW; Evans CP; Kung HJ
    Oncogene; 2004 Mar; 23(12):2197-205. PubMed ID: 14767470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
    Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
    Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
    Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer.
    Culig Z; Puhr M
    Mol Cell Endocrinol; 2012 Sep; 360(1-2):52-8. PubMed ID: 21664423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between IL-6/ERK and NF-κB: a study in normal and pathological human prostate gland.
    Rodríguez-Berriguete G; Prieto A; Fraile B; Bouraoui Y; de Bethencourt FR; Martínez-Onsurbe P; Olmedilla G; Paniagua R; Royuela M
    Eur Cytokine Netw; 2010 Dec; 21(4):241-50. PubMed ID: 21081304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
    Zerbini LF; Wang Y; Cho JY; Libermann TA
    Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways.
    Park JI; Lee MG; Cho K; Park BJ; Chae KS; Byun DS; Ryu BK; Park YK; Chi SG
    Oncogene; 2003 Jul; 22(28):4314-32. PubMed ID: 12853969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.
    Steiner H; Cavarretta IT; Moser PL; Berger AP; Bektic J; Dietrich H; Zaki MH; Nakada M; Hobisch A; Nemeth JA; Culig Z
    Prostate; 2006 Dec; 66(16):1744-52. PubMed ID: 16998813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.